al showed only modest responses to combination CPI therapy with nivolumab (anti-PD1) and ipilimumab (anti-CTLA4) as a first line treatment for pleural mesothelioma, although long term responders were established [27]. Here, CTLA4 is linked to pleural mesothelioma.